Olema Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals

San francisco, april 08, 2024 (globe newswire) -- olema pharmaceuticals, inc. (“olema”, “olema oncology”, nasdaq: olma), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that sean p. bohen, m.d., ph.d., president and chief executive officer, will participate in a panel on “breast cancer – shifting an entrenched paradigm” at the 2024 cg horizons in oncology virtual conference on monday, april 15, 2024, at 2:00 p.m. et.

San francisco, april 02, 2024 (globe newswire) -- olema pharmaceuticals, inc. (“olema” or “olema oncology”, nasdaq: olma), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the company granted stock options to two new employees to purchase an aggregate of 60,000 shares of the company's common stock, effective as of april 1, 2024. these awards were approved by the compensation committee of olema's board of directors and granted under the company's 2022 inducement plan, with a grant date of april 1, 2024, as an inducement material to the new employees entering into employment with olema, in accordance with nasdaq listing rule 5635(c)(4).

San francisco, march 11, 2024 (globe newswire) -- olema pharmaceuticals, inc. (“olema”, “olema oncology”, nasdaq: olma), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided a corporate update.

San francisco, march 06, 2024 (globe newswire) -- olema pharmaceuticals, inc. (“olema” or “olema oncology,” nasdaq: olma), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that molecular cancer therapeutics, an american association for cancer research journal, has selected as a featured article a data publication that describes the distinct properties of palazestrant (op-1250). the paper, titled “palazestrant (op-1250), a complete estrogen receptor antagonist, inhibits wild-type and mutant er-positive breast cancer models as monotherapy and in combination”, describes the scientific background underlying the design, discovery and optimization of palazestrant.

San francisco, march 04, 2024 (globe newswire) -- olema pharmaceuticals, inc. (“olema” or “olema oncology”, nasdaq: olma), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the company granted stock options to one new employee to purchase an aggregate of 50,000 shares of the company's common stock, effective as of march 1, 2024. these awards were approved by the compensation committee of olema's board of directors and granted under the company's 2022 inducement plan, with a grant date of march 1, 2024, as an inducement material to the new employees entering into employment with olema, in accordance with nasdaq listing rule 5635(c)(4).

SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on “Breast Cancer – Shifting an Entrenched Paradigm” at the 2024 CG Horizons in Oncology Virtual Conference on Monday, April 15, 2024, at 2:00 p.m. ET.

SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company will participate in the following upcoming investor conferences:

SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen, M.D., President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 9, 2024, at 5:15 p.m. PT (8:15 p.m. ET).

Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in progress will be presented on Dec. 7, 2023

Today, we revisit Olema Pharmaceuticals, Inc. for the first time in two years. Olema is a clinical-stage biotech company focused on developing therapies for women's cancers. Their primary product candidate, palazestrant, has been granted FDA Fast Track designation for the treatment of metastatic breast cancer. Palazestrant is advancing in development both as a potential monotherapy and as part of potential combination therapies.

Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.

SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company will present at the following upcoming investor conferences in November:

Olema Pharmaceuticals, Inc. (OLMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Olema Pharmaceuticals, Inc. (OLMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

While the health innovation space presents wild risks, you could potentially swing the odds in your favor with strong buy biotech stocks. Specifically, these ideas represent publicly traded biotechnology firms that enjoy the highest possible consensus rating among Wall Street analysts.